Touch Medical Media coverage of data presented at EADV 2023:
OLYMPIA 2 (NCT04501679) was a phase 3, multicentre, double-blind study that investigated the IL-31 inhibitor nemolizumab for the treatment of prurigo nodularis in adults.
touchDERMATOLOGY were delighted to speak with Prof. Adam Reich (University of Medicine, Wroclaw, Poland) around his analysis of OLYMPIA 2, looking at improvements in pain and patient reported outcomes.
The abstract ‘Nemolizumab modulates prurigo nodularis-associated skin pain and markedly improves patient reported outcomes in patients with moderate-to-severe prurigo nodularis in a phase 3 study (OLYMPIA 2).’ (Abstract N°: 4147) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress.
Questions
- What is the mechanism of action and rationale for investigating nemolizumab in prurigo nodularis? (0:18)
- Could you describe the aims and design of the phase 3 OLYMPIA 2 study, and how well the key endpoints were met? (0:50)
- What additional outcomes were investigated in your analysis of OLYMPIA 2 and how well were they met? (1:29)
- What will be the next steps in the clinical development of nemolizumab? (2:05)
Disclosures: Adam Reich discloses receiving grant/research support from Abbvie, Anaptys, BMS, Dice, Eli Lilly, Galderma, Incyte, Jannsen, Medac, Novartis, Pfizer, Regeneron, Trevi Therapeutics, and UCB; serving on advisory boards for Abbvie, Galderma, Leo Pharma, Sanofi, Novartis, and Eli Lilly.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.
Filmed in coverage of the EADV Annual Meeting.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
Click here for more content on prurigo nodularis & for further EADV 2023 highlights visit here.
